<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974204</url>
  </required_header>
  <id_info>
    <org_study_id>Exo-LCR-1807</org_study_id>
    <secondary_id>2018-A02358-47</secondary_id>
    <nct_id>NCT03974204</nct_id>
  </id_info>
  <brief_title>Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.</brief_title>
  <official_title>Benefit of Analyzing Exosomes in the Cerebrospinal Fluid During the Medical Care of Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, interventional, prospective study among breast cancer patients with a
      suspicion of metastatic meningitis. The current study aims to assess the use of proteomic
      profile issued from cerebrospinal fluid microvesicles for diagnosis of leptomeningeal
      metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to describe the association between the initial proteomic profile
      issued from cerebrospinal fluid microvesicles and the initial cytological analysis of the
      cerebrospinal fluid in breast cancer patients with a suspicion of metastatic meningitis.

      Other objectives of the study include:

        -  Describing the association between the initial proteomic profile and:

             -  the histological types and hormonal receptors status of the breast cancer,

             -  the likelihood of leptomeningeal metastasis according to the EANO-ESMO
                classification (Lack of evidence / possible / probable / confirmed) ,

             -  the likelihood of leptomeningeal metastasis according to the EANO-ESMO
                classification, combined with histological type and hormonal receptors status.

        -  Evaluate the prognostic value of the proteomic profiling for overall survival, according
           to the EANO-ESMO classification and other known prognosis factors, in patients
           classified &quot;possible&quot;, &quot;probable&quot; or &quot;confirmed&quot; leading to leptomeningeal metastases
           specific treatment,

        -  Evaluate the impact of the evolution of the proteomic profile a month after the start of
           this treatment on the overall survival, in patients with leptomeningeal metastases
           specific treatment,

        -  Evaluate the association between the proteomic profile and the EANO-ESMO classification
           at least 3 months after the initial EANO-ESMO classification,

        -  Evaluate the evolution of the proteomic profile 3 months after the initial EANO-ESMO
           classification, in patients initially classified &quot;lack of evidence&quot;, broadly and
           according to the evolution of cytology, the administered treatments and to the EANO-ESMO
           response if applicable,

        -  Compare the proteomic profiles issued from cerebrospinal fluid and blood
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteomic profiles issued from cerebrospinal fluid at diagnosis</measure>
    <time_frame>Up to 1 week</time_frame>
    <description>Proteomic profile will be obtained by bioinformatic analysis of cerebrospinal fluid.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytology of cerebrospinal fluid at diagnosis</measure>
    <time_frame>Up to 1 week</time_frame>
    <description>Results of cytological analysis of cerebrospinal fluid will be &quot;Positive&quot;, &quot;negative&quot;, &quot;equivocal&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proteomic profiles issued from cerebrospinal fluid</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Proteomic profile will be obtained by bioinformatic analysis of cerebrospinal fluid:
1 month and 3 month after the start of a specific treatment of the leptomeningeal metastasis, if applicable,
3 months after the initial diagnosis of leptomeningeal metastasis if the likehood of leptomeningeal metastasis is &quot;lack of evidence&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological subtype</measure>
    <time_frame>Before registration in study</time_frame>
    <description>Histological subtype will be subdivised as invasive ductal breast carcinoma, invasive lobular breast carcinoma, other brest carcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal receptors status</measure>
    <time_frame>Before registration in study</time_frame>
    <description>Hormonal receptors status will be subdivised as:
Positive hormonal receptors / Positive HER2
Positive hormonal receptors / Negative HER2
Negative hormonal receptors / Positive HER2
Triple negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likehood of leptomeningeal metastasis according to the EANO-ESMO classification.</measure>
    <time_frame>Up to 3 months after the intial diagnosis</time_frame>
    <description>EANO-ESMO classification is obtained by searching clinical symptoms, cancer cells in the cerebrospinal fluid (obtained by lumbar puncture), signs in RMI. The likehood of leptomeningeal metastasis is:
Lack of evidence,
Possible,
Probable,
Confirmed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from date of registration to date of death regardless of the cause, assessed up to 1 year</time_frame>
    <description>Overall survival is defined as time from date of registration to date of death regardless of the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomic profiles issued from blood</measure>
    <time_frame>Up to 3 months after the intial diagnosis</time_frame>
    <description>Proteomic profile will be obtained by bioinformatic analysis of blood.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Leptomeningeal Metastasis</condition>
  <arm_group>
    <arm_group_label>Cerebrospinal fluid and Blood sample collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Collection of cerebrospinal fluid and blood samples:
At initial diagnostic assessment;
1 month and 3 months after initial diagnostic assessment, for patients classified &quot;possible&quot;, &quot;probable&quot; or &quot;confirmed&quot; according to EANO-ESMO classification, leading to specific leptomeningeal metastase treatment;
In case of symptoms leading to leptomeningeal metastase suspicion and at least 3 months after diagnostic assessment, for patients classified &quot;lack of evidence&quot; according to EANO-ESMO classification.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment</intervention_name>
    <description>At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.</description>
    <arm_group_label>Cerebrospinal fluid and Blood sample collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are &quot;Lack of evidence&quot; according to EANO-ESMO classification</intervention_name>
    <description>3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:
When suspected metastatic meningitis symptoms arise and
at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.</description>
    <arm_group_label>Cerebrospinal fluid and Blood sample collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are &quot;confirmed&quot;, &quot;probable&quot; or &quot;possible&quot;, leading to leptomeningeal metastase specific treatment</intervention_name>
    <description>3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:
1 month after the beginning of the specific treatment,
3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment.</description>
    <arm_group_label>Cerebrospinal fluid and Blood sample collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with histologically proven breast cancer

          -  Patient with suspected metastatic leptomeningitis

          -  Age ≥ 18 years

          -  Patient covered by the French social security regime

          -  Signed written informed consent

        Exclusion Criteria:

          -  History of cancer other than the one being treated

          -  Contraindication to carrying out the lumbar puncture or cerebrospinal MRI

          -  Pregnant or breastfeeding patient
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie LE RHUN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien THERY</last_name>
    <phone>+33 (0)3 20 29 59 18</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de- France</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emilie LE RHUN, MD</last_name>
      <phone>+33 (0)3 20 29 59 35</phone>
      <email>e-lerhun@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie LE RHUN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence VANLEMMENS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey MAILLIEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de-France</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emilie LE RHUN, MD</last_name>
      <phone>+33 (0)3 20 44 59 62</phone>
      <email>emilie.lerhun@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie LE RHUN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe DESAUW, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebrospinal fluid</keyword>
  <keyword>Proteomic profile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

